acne

Topical inhibits sebum to control acneThe investigational sebum-inhibiting topical DRM01 had positive results in a phase 2b study, which paves the way for phase 3 trials planned for 2017.
GlobalMed Technologies acquires Omnilux MedicalGlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.
Diet, skin disease data growingA growing number of studies suggest diet influences general skin health and specific skin diseases, from acne and eczema to skin aging. Dermatologists share their best practices for using diet to combat skin disease and promote skin health.
Energy-based treatment advantages for acneTwo novel energy-based approaches are ushering in a new era in acne treatment. One expert addresses the role these devices may play.
Isotretinoin: Time to reconsider blood test best practicesWhile oral isotretinoin has been associated with various side effects and routine blood tests have been recommended, evidence points to inconsistencies in monitoring practices. Many physicians also are questioning whether the effort has value.
Inflammasomes role in acne solidifiesExperts discuss association between inflammasomes and acne that may lead to treatments stopping acne before clinical signs emerge.
Data support acne dietary triggersNew findings support dietary and supplementation practices that can influence acne. One expert discusses modifications in context of protocols for managing the condition.
New and emerging treatment options for acneWhile many are in early phase studies, most of the new topical options are targeting sebum reduction, a novel pathway to controlling acne, and the data are exciting, one expert says.